Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
The Lancet. Global Health
|
November 6, 2016
The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial
Audrey Pettifor, Catherine MacPhail, James P Hughes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 29, 2021
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
Jyoti S Mathad, Rada Savic, Paula Britto, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 10, 2023
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
Supattra Rungmaitree, Linda Aurpibul, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 10, 2022
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014
Ann J Melvin, Ka Lai Yee, Kathryn P Gray, et al.
Clinical Pharmacokinetics
|
August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
Hardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
AIDS (London, England)
|
April 8, 2021
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
Christine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, et al.
The Lancet. HIV
|
April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial
Theodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Helena Rabie, Dwight E Yin, Shawn Ward, et al.
The Lancet. HIV
|
January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
Elizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV
|
January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
The Lancet. Global Health
|
November 6, 2016
The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial
Audrey Pettifor, Catherine MacPhail, James P Hughes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 29, 2021
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
Jyoti S Mathad, Rada Savic, Paula Britto, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 10, 2023
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
Supattra Rungmaitree, Linda Aurpibul, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 10, 2022
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014
Ann J Melvin, Ka Lai Yee, Kathryn P Gray, et al.
Clinical Pharmacokinetics
|
August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
Hardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
AIDS (London, England)
|
April 8, 2021
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
Christine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, et al.
The Lancet. HIV
|
April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial
Theodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Helena Rabie, Dwight E Yin, Shawn Ward, et al.
The Lancet. HIV
|
January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
Elizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV
|
January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
Page
of 3